Evidence map›Paper›PMID 30144429›Full record

Trial reportGastroenterology2018

FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.

Elliot S Friedman, Yun Li, Ting-Chin David Shen, Jack Jiang, Lillian Chau, Luciano Adorini, Farah Babakhani, Jeffrey Edwards, David Shapiro, Chunyu Zhao and 4 more

Registry-linked trialAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01933503 (An Open Label, Randomized, Single Dose and Multiple Dose Trial to Assess the Pharmacokinetics of Obeticholic Acid), which is not on this map. Cited by 97 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01933503 phase1completednot on this map

An Open Label, Randomized, Single Dose and Multiple Dose Trial to Assess the Pharmacokinetics of Obeticholic Acid (OCA)

TypeinterventionalSponsorIntercept PharmaceuticalsRan2013 to 2013Enrolled24ConditionsHealthyArmsOCA 5 mg, OCA 10 mg, OCA 25 mg
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. A Review on the Molecular Dynamics of EnterotypeInternational journal of molecular sciences · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. International journal of molecular sciences · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Elliot S FriedmanDivision of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Yun LiDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Ting-Chin David ShenDivision of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jack JiangDivision of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Lillian ChauDivision of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Luciano AdoriniIntercept Pharmaceuticals, San Diego, California.
Farah BabakhaniIntercept Pharmaceuticals, San Diego, California.
Jeffrey EdwardsIntercept Pharmaceuticals, San Diego, California.
David ShapiroIntercept Pharmaceuticals, San Diego, California.
Chunyu ZhaoDivision of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Rotonya M CarrDivision of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Kyle BittingerDivision of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Hongzhe LiDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Gary D WuDivision of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: gdwu@pennmedicine.upenn.edu.
University of Pennsylvania · USIntercept Pharmaceuticals (United States) · USChildren's Hospital of Philadelphia · US

Funding

VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL A. LAZAR · 1986 to 2026
$48.3M
TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI REBECCA G WELLS · 1997 to 2026
$32.5M
Statistical Methods for Microbiome and MetagenomicsR01GM123056 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI LEE, HONGZHE · 2017 to 2025
$3.7M
Molecular Mechanisms Of Post-Transplant Recurrent Alcoholic Liver DiseaseR01AA026302 · NIAAA · UNIVERSITY OF WASHINGTON · PI ROTONYA M CARR · 2017 to 2026
$3.2M
The pathogenesis of insulin resistance in alcoholic liver diseaseK08AA021424 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI CARR, ROTONYA M · 2013 to 2017
$918k
Role of Bacterial Urease in Host and Gut Microbiota Amino Acid MetabolismK08DK106457 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SHEN, TING-CHIN DAVID · 2017 to 2022
$845k
NIAAA NIH HHS K08 AA021424NIAAA NIH HHS R01 AA026302NIDDK NIH HHS K08 DK106457NIDDK NIH HHS P30 DK019525NIDDK NIH HHS P30 DK050306NIGMS NIH HHS R01 GM123056
6 · The paper itself

Abstract

BACKGROUND &

aimsIntestinal bacteria can modify the composition of bile acids and bile acids, which are regulated by the farnesoid X receptor, affect the survival and growth of gut bacteria. We studied the effects of obeticholic acid (OCA), a bile acid analogue and farnesoid X receptor agonist, on the intestinal microbiomes of humans and mice.

methodsWe performed a phase I study in 24 healthy volunteers given OCA (5, 10, or 25 mg/d for 17 days). Fecal and plasma specimens were collected at baseline (day 0) and on days 17 (end of dosing) and 37 (end of study). The fecal specimens were analyzed by shotgun meta-genomic sequencing. A Uniref90 high-stringency genomic analysis was used to assign specific genes to the taxonomic signature of bacteria whose abundance was associated with OCA. Male C57BL/6 mice were gavage fed daily with water, vehicle, or OCA (10 mg/kg) for 2 weeks. Small intestine luminal contents were collected by flushing with saline and fecal pellets were collected at baseline and day 14. Mouse samples were analyzed by 16S-tagged sequencing. Culture experiments were performed to determine the taxonomic-specific effects of bile acids and OCA on bacterial growth.

resultsSuppression of endogenous bile acid synthesis by OCA in subjects led to a reversible induction of gram-positive bacteria that are found in the small intestine and are components of the diet and oral microbiota. We found that bile acids decreased proliferation of these bacteria in minimum inhibitory concentration assays. In these organisms, there was an increase in the representation of microbial genomic pathways involved in DNA synthesis and amino acid metabolism with OCA treatment of subjects. Consistent with these findings, mice fed OCA had lower endogenous bile acid levels and an increased proportion of Firmicutes, specifically in the small intestine, compared with mice fed water or vehicle.

conclusionsIn studying the effects of OCA in humans and mice, we found evidence for interactions between bile acids and features of the small intestinal microbiome. These findings indicate that farnesoid X receptor activation alters the intestinal microbiota and could provide opportunities for microbiome biomarker discovery or new approaches to engineering the human microbiome. ClinicalTrials.gov, NCT01933503.

Indexed as

AdultAnimalsBile Acids and SaltsChenodeoxycholic AcidFemaleGastrointestinal MicrobiomeHealthy VolunteersHumansIntestine, SmallMaleMiceMice, Inbred C57BLReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearBile Acids and SaltsChenodeoxycholic Acidobeticholic acidReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearGene RegulationGeneticsMetabolismNuclear Hormone Receptor

Identifiers

PMID30144429
PMCPMC6279623
OpenAlexW2888639734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.